Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt)

Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) is an essential enzyme that catalyzes the phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), a critical step in bacterial DNA synthesis[3][2]. The enzyme is classified as a kinase (transferase family) and displays structural features distinct from human thymidylate kinases, including a unique arrangement of active site residues and a distinctive magnesium-binding site necessary for catalysis[1][2]. TMPKmt is validated as a promising antibacterial drug target due to its indispensable role in DNA replication and cell viability of M. tuberculosis, and its structural differences have enabled the design of selective inhibitors[3][4]. No TMPKmt-directed drugs are clinically approved, but diverse chemical scaffolds show potent, selective enzyme inhibition in vitro and are considered leads for antitubercular agent development[3][4].

Other names

Mycobacterium tuberculosis TMP kinaseThymidylate kinase (M. tuberculosis)dTMP kinase (M. tuberculosis)TMPK(Mtub)

Inhibitors generally act by competitive inhibition of the thymidine monophosphate binding or by occupying/inactivating the active site, preventing the enzyme from facilitating phosphorylation necessary for DNA synthesis[3][4]. Some compounds show high selectivity for the bacterial enzyme over human TMPK, exploiting differences in the active site structure[3].